Testing DT-101 against a placebo for major depressive disorder in adults
Tests whether DT-101 can treat major depressive disorder in adults.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Key facts
- Where
- Gdansk, Katowice, and Poznan, PolandSee the 3 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with recurrent depression (major depressive disorder). It tests the drug DT-101 against a placebo.
- Age
- 18 to 75 years
- Sex
- Men and women (all gender identities)
- Disease stage
- Recurrent depression: at least one earlier depression episode besides the current one, diagnosed by DSM 5-TR criteria.
Main reasons for not taking part
- Pregnant, breastfeeding or planning to become pregnant during the study
- Unstable medical condition or unstable chronic disease
- Significant neurological abnormality
- Moderate or severe alcohol or drug use disorder in the 6 months before screening
- History of seizure
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07300969, who can take part
Where in Poland
- GdanskGdansk, PolandTaking people
- KatowiceKatowice, PolandTaking people
- PoznanPoznan, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Draig Therapeutics Ltd
- Trial code
- NCT07300969
- Record updated
- 8 October 2026
- Original description
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.Read full original descriptionShow less
A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.
Inclusion: The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent; Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent; Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).
Exclusion: History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening; Unstable medical condition or unstable chronic disease; History of seizure; Pregnant or breastfeeding or plans to become pregnant during the study; Significant neurological abnormality; In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.